The CALLY index, initially introduced by Iida et al. in the context of hepatocellular carcinoma, integrates CRP, albumin, and lymphocyte count, thereby reflecting systemic inflammation, nutritional status, and immune function. The gene discussed is CRP; the disease is hepatocellular carcinoma.